Multifunctional Nanoparticles for Combinational Cancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1094
Special Issue Editors
Interests: focused ultrasound; nanoparticle; noninvasive and targeted brain drug delivery; blood-brain barrier opening; brain cancer; glymphatic; Alzheimer’s disease
Special Issue Information
Dear Colleagues,
Over the past decade, nanotechnology has demonstrated significant potential in addressing major challenges in cancer therapy, such as minimizing dose-associated toxicity, multidrug resistance, and non-specific delivery. Nevertheless, the limited therapeutic effect of anticancer drugs or treatments is still an issue. The development of new cancer drugs is very cost extensive and time-consuming. Therefore, the scientific focus has shifted from developing new anticancer drugs to combining multiple existing cancer therapies, also known as combinational therapy, to achieve a synergistic or additional therapeutic effect. Nanotechnology-assisted combinational therapies enable the design of multifunctional nanocarriers to control drug release at specific diseased sites that can also respond to internal or external stimuli. The efficacy of combinational therapy is determined by various factors such as pharmacokinetics of different drugs, logical drug combinations, effective drug ratios, and dosage, sequence of release, and identification of precise targets for site-specific delivery. A deeper understanding of the aforementioned parameters is crucial to attaining the optimal therapeutic response.
This Special Issue aims to present recent advances in the investigation and development of multifunctional nanoparticles (organic, inorganic, composite, and carbon-based) for combinational cancer therapy. Authors are invited to submit original and review articles that contribute to this exciting research field.
Dr. Muna Aryal
Dr. Binita Shrestha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multifunctional
- nanoparticles
- combinational therapy
- cancer
- nanocarriers
- nanomedicine
- nanomaterials
- synergistic
- drug repurposing
